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Abstract: 
5-hydroxytryptamine (5-HT) is pro-arrhythmic in atrial cells from patients in sinus rhythm (SR) 
via activation of 5-HT4 receptors, but its effects in atrial cells from patients with atrial 
fibrillation (AF) are unknown. The whole-cell perforated patch-clamp technique was used to 
record L-type Ca
2+
 current (ICaL), action potential duration (APD) and arrhythmic activity at 
37ºC in enzymatically-isolated atrial cells obtained from patients undergoing cardiac surgery, in 
SR or with chronic AF. In the AF group, 5-HT (10 µΜ) produced an increase in ICaL of 
115±21% above control (n=10 cells, 6 patients) that was significantly smaller than that in the 
SR group (232±33%; p<0.05; n=27 cells, 12 patients). Subsequent co-application of 
isoproterenol (1 µΜ) caused a further increase in ICaL in the AF group (by 256±94%) that was 
greater than that in the SR group (22±6%; p<0.05). The APD at 50% repolarisation (APD50) 
was prolonged by 14±3 ms by 5-HT in the AF group (n=37 cells, 14 patients). This was less 
than that in the SR group (27±4 ms; p<0.05; n=58 cells, 24 patients). Arrhythmic activity in 
response to 5-HT was observed in 22% of cells in the SR group, but none was observed in the 
AF group (p<0.05). Atrial fibrillation was associated with reduced effects of 5-HT, but not of 
isoproterenol, on ICaL in human atrial cells. This reduced effect on ICaL was associated with a 
reduced APD50 and arrhythmic activity with 5-HT. Thus, the potentially arrhythmogenic 
influence of 5-HT may be suppressed in AF-remodelled human atrium. 
 
 
Keywords: patch-clamp; myocytes; atrial fibrillation; L-type calcium current; action potentials; 
5-HT; isoproterenol. 
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Introduction 
Atrial fibrillation (AF) is the most common sustained arrhythmia in the developed word and its 
prevalence will increase with the ageing of the population [1]. The occurrence of AF may be 
related to structural heart disease, but in many cases there is not a clear aetiology. One of the 
factors that has been postulated to be responsible for the origin and maintenance of AF is the 
release of 5-hydroxytryptamine (5-HT, serotonin) from aggregating platelets in human atria 
[2,3]. 5-HT is a naturally occurring monoamine, widely distributed in the animal kingdom, 
which exerts complex effects throughout the body, including the gastrointestinal and 
cardiovascular systems [4,5]. 5-HT has been shown to act, via 5-HT4 receptors [6], as a positive 
inotropic, chronotropic and lusitropic agent in the human atrium [7]. 5-HT increases the L-type 
Ca
2+ 
current, ICaL, using the same biochemical pathway as isoproterenol (ISO), a β-adrenoceptor 
agonist, through activation of cyclic AMP [8]. The 5-HT-induced increase in peak ICaL density 
has been associated with a prolongation of the early plateau phase of the action potential 
duration (APD50) and with arrhythmic activity in atrial myocytes from patients in sinus rhythm 
(SR) [9]. However, it is not known if the ability of 5-HT to increase ICaL, APD50 and induce 
arrhythmic activity is preserved in atrial myocytes from patients with chronic AF. Another 
factor that may influence the arrhythmogenic potential of 5-HT is chronic β-adrenoceptor 
antagonist treatment of patients in SR prior to surgery [9-11]. The ability of 5-HT to increase 
ICaL, APD50 and to cause arrhythmic activity in human atrial myocytes is increased by chronic β-
blockade in myocytes from patients in SR [9], but the influence of chronic β-blockade on the 
electrophysiological effects of 5-HT in myocytes from patients with AF is unknown. There has 
been only one previous study of 5-HT and AF, which showed a reduction of mRNA expression 
of 5-HT4 receptors, but not of β-adrenoceptors, in the fibrillating human atrium [12]. 
The aims of this study were to investigate the effects of 5-HT with and without ISO on ICaL, 
action potential duration (APD), cellular effective refractory period (cERP) and cellular 
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arrhythmic depolarisations (cADs) in atrial myocytes from patients with chronic AF, and to 
compare these with the effects in atrial myocytes from patients in SR. We also assessed the 
influence of chronic treatment of patients with a β-adrenoceptor antagonist on the 
electrophysiological actions of 5-HT in atrial myocytes from patients with and without AF. 
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Methods 
 
 
Tissue and cell isolation 
Procedures for obtaining human tissue were approved by the local ethical committee and 
conform to the institutional guidelines. This investigation conforms to the principles outlined in 
the Declaration of Helsinki [13]. Samples of the right atrial appendage were obtained from 81 
consenting patients undergoing cardiac surgery; 66 in SR and 15 in chronic AF. Cardiac rhythm 
was determined from the pre-operative electrocardiogram, and duration of AF was confirmed 
from the patients’ medical records. Atrial myocytes were isolated enzymatically as described 
previously [9].  
 
 
Electrical recording techniques 
The whole-cell perforated patch-clamp technique was used to record ICaL, APD, cERP and cADs 
as described before [9]. Cells were superfused at 37
o
C with a physiological solution containing 
(mM): NaCl (130), KCl (4), CaCl2 (2), MgCl2 (1), glucose (10), HEPES (10), pH 7.4. To record 
ICaL, a pipette solution containing (mM): CsCl (30), HEPES (5), MgCl2 (1), Cs methanesulfonic 
acid (100), NaCl (5), nystatin (0.18) was used. To record action potentials, a pipette solution 
containing (mM): KCl (30), HEPES (5), MgCl2 (1), K methanesulfonic acid (100), NaCl (5), 
nystatin (0.18) was used. Using these solutions, a liquid junction potential of +5.0±0.2 mV 
(n=6) was measured (bath relative to pipette) and was compensated for prior to seal formation. 
The series resistance in cells from patients with and without AF was 9.5±0.3 MΩ (n=99 cells) 
and 10.4±0.2 MΩ (n=352 cells), with a mean cell capacity of 92±2 pF and 78±1 pF (p<0.05), 
respectively. Capacitative transients were compensated electronically from the recordings, and 
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the voltage drop across the series resistance was also compensated (68-80%). The software 
program WinWCP (J. Dempster, University of Strathclyde, UK) was used to stimulate and 
record electrical activity.  
 
 
Experimental protocols 
The voltage-dependency of ICaL was measured from a holding potential of -40 mV, with pulses 
of 250 ms duration at 0.33 Hz increasing in steps of 10 mV, up to +40 mV. The time-dependent 
effect of drugs was measured on peak ICaL with depolarising pulses from -40 to +10 mV (0.2 
Hz). Actions potentials were stimulated at the physiological rate of 75 beats/min (bpm) using 5 
ms current pulses of 1.2x threshold strength, after current clamping resting cells at -80 mV, and 
keeping the holding current (<150 pA) constant thereafter throughout all recording protocols in 
each cell. The holding current density (pA/pF) was found not to be significantly different 
between cells from patients in SR and AF, with or without prior treatment with a β-adrenoceptor 
antagonist. The cellular ERP was measured using a standard S1-S2 stimulation protocol, with an 
8-pulse conditioning train delivered at 75 bpm, and with S1 and S2 pulses of equal magnitude. 
The S1-S2 interval was shortened in 10 ms steps, and the cERP was defined as the longest S1-S2 
interval which failed to elicit an S2 action potential of amplitude >80% of the preceding S1 
action potential. The APD was calculated as the interval between the action potential upstroke 
and repolarisation to the level of 50% (APD50) and 90% (APD90) of the upstroke amplitude. ICaL 
and/or action potentials and the cERP were recorded before, and 90 s after, drug additions and 
again 180 s after removal of drugs. The spontaneous development of cellular arrhythmic 
depolarisations was recorded during the measurement of the cERP protocol. Cellular ADs were 
defined as any transient depolarisation during phase 3 or a transient depolarisation of >3mV 
during phase 4. 
  
7 
 
Data analysis and statistics 
Cells were excluded from analysis if either the APD50 or peak ICaL decreased irreversibly during 
the protocol. Concentration-response data for the effect of 5-HT on peak ICaL were fitted 
iteratively (Graphpad Prism) using a variable slope sigmoidal concentration-response curve. 
Time-dependent inactivation of peak ICaL was fitted by a bioexponential function [21]. All data 
have been analysed using cell means, except when stated that patient means were used. Mean 
±standard error of the mean (SEM) values were compared using paired or unpaired Student’s t-
test, with p<0.05 regarded as statistically significant. A Fisher’s exact test was used to assess the 
incidences of arrhythmic activity between groups of cells. To permit sub-analysis within the SR 
group, data have been used from 27 patients in SR who were included in a previous publication 
[9]. 
 
 
Drugs 
5-HT and ISO (Sigma) were prepared as 10 mM stock solution in distilled water. Nifedipine 
(Sigma) and GR-113808 (a gift from Johnson & Johnson Pharmaceutical Research & 
Development) were dissolved in dimethyl sulfoxide at 10 mM and subsequently diluted in 
physiological solutions. 
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Results 
 
 
Patients’ clinical characteristics  
Clinical characteristics of patients in SR or with chronic AF (>6 months) are shown in Table 1. 
Those patients with prior treatment with β-adrenoceptor antagonists were treated for at least 1 
week. In the SR group, the majority received a cardiac selective β1-adrenoceptor antagonist, 
namely atenolol (77% of patients), bisoprolol (17%), metoprolol (4%); 1 patient received the 
cardiac non-selective β-adrenoceptor antagonist, propranolol (2%). Those patients with AF were 
treated with atenolol (57%), bisoprolol (29%) or with the cardiac non-selective β-adrenoceptor 
antagonist, carvedilol (14%). Patients received their routine drugs on the day of surgery. Mean 
ventricular rate was 66±2 bpm in 66 patients in SR versus 69±5 bpm in 15 patients with AF 
(p>0.05). The ventricular rate was reduced in β-blocked (60±2 bpm, n=47) compared to non-β-
blocked patients (76±3 bpm, p<0.05; n=19) from the SR group of patients. In patients with AF, 
the ventricular rate was similar in β-blocked (72±7 bpm, n=8) compared to non-β-blocked 
patients (66±7 bpm, p>0.05; n=7).  
 
Effects of 5-HT on ICaL and influence of chronic AF 
The density of basal peak ICaL was smaller in cells from patients with AF (-3.0±0.2 pA/pF; n=50 
cells, 14 patients) than in cells from those in SR (-5.4±0.3 pA/pF, p<0.05; 178 cells, 58 
patients). Within the AF group of patients, no significant difference was found in basal ICaL 
between patients who had (-2.9±0.2 pA/pF; n=9) and who had not (-3.2±0.3 pa/pF; n=5) 
undergone mitral valve replacement (MVR) surgery. Examples of original ICaL recordings from 
a cell from a patient in SR or with AF are shown in Figure 1 in the absence (upper panel) or in 
the presence (lower panel) of 5-HT (10 µM). The 5-HT-induced increase in the mean magnitude 
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of ICaL in cells from patients with and without AF is shown in Figure 1 (inset). This increase in 
ICaL occurred without any change in its voltage dependency, and was reversible on washout of 5-
HT. 
The concentration-response curves of the effect of 5-HT on peak ICaL density (pA/pF) obtained 
in cells from patients with and without AF, are shown in Figure 2A. 5-HT (0.001-10 µM) 
elicited a concentration-dependent increase in the amplitude of peak ICaL, with a maximum 
response (Emax) equal to an increase of 187±2% above control in cells from patients with AF. 
This was significantly less than that produced by 5-HT in cells from patients in SR 
(Emax=260±7%; p<0.05; Figure 2B). In addition, the concentration of 5-HT producing half-
maximal response (expressed as logEC50) was significantly higher in cells from patients with 
AF (-6.35±0.02) than in cells from those in SR (-6.84±0.17; p<0.05), indicating a reduced 
potency of 5-HT (Figure 2C). The Hill coefficient, a measure of cooperativity of the agonist 
with the receptor, was 0.68±0.02 in cells from patients with AF, not significantly different than 
in cells from those in SR (0.66±0.14). A higher concentration of 5-HT (100 µM) caused a 
significantly smaller ICaL response in comparison to the 10 µM 5-HT in all cells studied, with 
and without AF (not shown). The 5-HT4 antagonist GR-113808 at 1 µM blocked the 5-HT-
induced increase of peak ICaL in cells from patients in SR (n=4 cells, 2 patients) or with AF (n=4 
cells, 2 patients). Basal peak ICaL was abolished by the Ca
2+
 channel blocker nifedipine at 10 µM 
in cells from patients in SR (3 cells, 2 patients) or with AF (3 cells, 2 patients).  
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Effects of 5-HT on ICaL and influence of chronic β-blockade 
Chronic β-blockade did not significantly affect basal peak ICaL in cells from patients in SR (-
5.5±0.3 vs -5.0±0.5 pA/pF; n=137 cells from 41 β-blocked patients and n=41 cells from 17 non 
β-blocked patients, respectively) or with AF (-3.2±0.3 vs -2.9±0.3 pA/pF; n=24 cells from 7 β-
blocked patients and n=26 cells from 7 non β-blocked patients). The influence of chronic 
treatment of patients with a β-adrenoceptor antagonist on the concentration-response curves of 
the effect of 5-HT on peak ICaL obtained in cells from patients with and without AF is shown in 
Figure 3A. The Emax of the increase in ICaL by 5-HT was greater in cells from β-blocked patients 
compared with non β-blocked patients in the AF group (205±4% vs 158±1%; p<0.05) and SR 
groups (282±14% vs 216±4%; p<0.05; Figure 3B), respectively. Neither the potency (Figure 
3C) nor the nH of the 5-HT concentration-response curve were affected by chronic treatment of 
patients with a β-adrenoceptor antagonist with and without AF. Similar increases in Emax by 5-
HT were obtained when the comparisons were made of patient means, from β-blocked and non 
β-blocked patients in AF (234±5% vs 171±2%; p<0.05) or SR (316±17% vs 231±4%; p<0.05), 
respectively. 
 
 
Effects of 5-HT, with and without ISO, on ICaL, and influence of chronic AF 
In subsets of cells from patients with or without AF, the application of a maximal concentration 
of 5-HT (10 µM) was followed by the co-application of a maximal concentration of ISO (1 
µM), in order to assess the ability of β-adrenoceptors to increase peak ICaL after saturation of 5-
HT4 receptors. Figures 4A and 4B show examples of this protocol, from a cell from a patient in 
SR or with AF, respectively. 5-HT produced an increase in peak ICaL that was significantly 
greater in cells from patients in SR than that in cells from patients with AF (232±33 vs 
115±21% above control; p<0.05; Figure 4C). Subsequent co-application of ISO further 
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increased peak ICaL in both groups, but by a relatively greater increase in cells from patients 
with AF (256±94% greater than with 5-HT alone) than in cells from patients in SR (22±6% 
greater than with 5-HT; p<0.05). Although the absolute ICaL density in the presence of 5-HT 
with or without ISO was significantly less in cells from patients with AF than that in cells from 
patients in SR (Figure 4C), the relative increase with ISO (to 273±38% above control, p<0.05, 
with SR; and to 324±56% above control, p<0.05, with AF) was not significantly different 
between the groups (p>0.05). Following washout of 5-HT and ISO, the subsequent application 
of ISO alone increased ICaL, in a similar manner to the co-application of ISO with 5-HT, in both 
groups (Figure 4C). 
In the same set of cells, we analysed the kinetics properties of the time-dependent inactivation 
of basal and stimulated peak ICaL (Table 2). The fast (τ1) and the slow (τ2) inactivation time 
constants were increased in cells from patients with AF compared to cells from patients in SR. 
5-HT had no significant effect on τ1 and τ2 in cells from patients with and without AF. 
However, their respective fractions A1 and A2 were altered by shifting the ICaL inactivation from 
the fast to the slow phase. Co-application of 5-HT with ISO decreased τ1, but not τ2, in both 
group of cells, and this was associated with a reduced A1 and an increased A2. 
 
 
Effects of 5-HT on APD characteristics and influence of chronic AF  
The basal APD50 was longer in cells from patients with AF (40±3 ms; n=37 cells, 14 patients) 
compared to cells from patients in SR (17±2 ms, p<0.05; n=58 cells, 24 patients). By contrast, 
the APD90 was significantly shortened in cells from patients with AF (203±8 ms) compared to 
cells from patients in SR (239±11 ms; p<0.05). Within the AF group of patients, no significant 
differences were found in basal APD characteristics between patients who had (n=5) and who 
had not (n=9) undergone MVR surgery. Figure 5A shows original traces of action potential 
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recordings illustrating the effects of 5-HT in a cell from a patient in SR (left panel) or with 
AF (right panel), both treated with a β-adrenoceptor antagonist. In these examples, 5-HT (10 
µM) caused a prolongation of the APD50, without affecting the late repolarisation and the cERP. 
Mean data demonstrated that the 5-HT-induced prolongation of the APD50 in the AF group was 
significantly smaller than that in the SR group (Figure 5B; p<0.05). This effect was fully 
reversible after 3 min washout. There was no significant effect of 5-HT on other action potential 
measurements including APD75, APD90, cERP, overshoot, amplitude and maximum upstroke 
velocity in either the cells from patients in SR or with AF. 
 
 
Effects of 5-HT on APD characteristics and influence of chronic β-blockade 
In cells from patients in SR, 5-HT produced a significantly greater prolongation of APD50 in 
cells from β-blocked (36±6 ms; n=37 cells, 15 patients) than non β-blocked patients (10±3 ms, 
p<0.05; n=21 cells, 9 patients). By contrast, in cells from patients with AF, there was no 
significant difference in the 5-HT-induced prolongation of the APD50 between cells from the β-
blocked (18±5 ms; n=25 cells, 8 patients) and non β-blocked patients (9±3 ms, p>0.05; n=12 
cells, 7 patients). These findings were confirmed by using patient means for both β-blocked 
patients and non β-blocked patients in SR (33±6 vs 9±3 ms; p<0.05) or AF (16±4 vs 9±4 ms; 
p>0.05), respectively.  
 
 
Effects of 5-HT, with and without ISO, on APD characteristics, and influence of chronic 
AF 
In a subset of cells, we investigated effects on action potentials of the co-application of ISO (1 
µM) and 5-HT (10 µM), following 5-HT alone, i.e. using the same protocol described earlier for 
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ICaL. Figure 6A shows examples of such effects in a cell from a patient in SR (left panel) or 
with AF (right panel). Mean data from 10 cells (3 patients) indicated that ISO may further 
prolong APD50 in cells from patients with AF (from 60±7 to 74±9 ms; p<0.05; n= 10 cells, 3 
patients), but not in cells from patients in SR (from 63±9 to 69±9 ms; p>0.05; n=16 cells, 5 
patients), with no significant effects on APD75, APD90 and the cERP. GR-113808 (1 µM) 
prevented the increase induced by 5-HT (10 µM) of APD50 in cells from patients in SR (n=8 
cells, 3 patients) or with AF (n=3 cells, 1 patient), but not that of ISO (1 µM) in cells from 
patients in SR (7 cells, 3 patients) or with AF (2 cells, 1 patients).  
 
 
Effects of 5-HT, with and without ISO, on cADs, and influence of chronic β-blockade 
Cellular arrhythmic depolarisations were not observed in any of the 37 cells from 14 patients 
with AF to which 10 µM 5-HT was applied. In contrast, when 10 µM 5-HT was applied in 58 
cells from 24 patients in SR, cADs, consistent with early and delayed afterdepolarisations, 
occurred in 13 of the cells studied (22%) from 9 patients (38%) (p<0.05; Fisher’s exact test). 
These cADs in response to 5-HT were observed only in cells obtained from β-blocked patients 
(13 of 37 cells), while none were observed in cells from the non β-blocked patients (0 of 21 
cells; p<0.05). This difference remained significant when the comparison was made by patient 
means (p<0.05). In a subset of cells from patients with and without AF (Figure 6B), when ISO 
(1 µM) was co-applied with 5-HT (10 µM), we observed the appearance of cADs in 15 out of 
16 cells (94%) studied from 5 patients in SR and in 3 out of 11 cells (27%) from 3 patients with 
AF. Both nifedipine and GR-113808 prevented the 5-HT-induced cADs in cells from patients in 
SR (4 cells from 2 patients and 8 cells from 3 patients, respectively). However, while GR-
113808 did not prevent the ISO-induced cADs in cells from patients in SR (7 cells, 3 patients) 
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or with AF (2 cells, 1 patients), nifedipine did in cells from patients in SR (2 cells, 1 patient) 
or with AF (3 cells, 2 patients). 
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Discussion  
This study is the first, to our knowledge, to report that AF is associated with a reduction of the 
effects of 5-HT on ICaL and APD50 in human atrial cells. This was associated with a loss of 
arrhythmic activity in cells from patients previously treated with a β-adrenoceptor antagonist. 
The pro-arrhythmic actions of 5-HT in humans have been known for a long time [14] and 
support for its pro-arrhythmic effects has been reported in several studies from patients in SR 
[2,9,10], but there are no reports from patients with AF. Our study supports the hypothesis that 
5-HT may play a role in initiating AF by promoting ectopic activity in patients in SR, that is 
enhanced by chronic treatment of patients with a β-adrenoceptor antagonist. However, once the 
arrhythmia is maintained and the remodelling process has occurred, 5-HT has a reduced efficacy 
and potency in activating the L-type Ca
2+
 channels. Therefore, despite the possible release of 5-
HT in the fibrillating atria by platelets [2], its arrhythmic influence may be attenuated. This 
suggests that the remodelling processes induced by chronic AF may involve an adaptive 
response including protection from these effects of 5-HT. In addition, since late repolarisation 
and cERP were unaffected by application of 5-HT in cells from patients with and without AF, it 
is unlikely that 5-HT plays a role in maintaining the arrhythmia by affecting the minimum path 
length required for re-entry [15]. The absence of arrhythmic activity by 5-HT in cells from 
patients with AF, and the low incidence of arrhythmic activity found in cells from patients in 
SR, are in line with a lack of clinical evidence to support 5-HT as a major factor involved in 
initiating and maintaining AF in humans [3]. Indeed, even in 5-HT-secreting tumour diseases 
like the carcinoid syndrome, in which high plasma levels of 5-HT have been detected, the 
incidence of AF is low [2,3].  
The mechanisms involved in the reduction of the electrophysiological actions of 5-HT in cells 
from patients with AF are not clear. The involvement of the 5-HT4 receptors and the L-type 
Ca
2+
 channels in the actions of 5-HT in these cells has been established by the prevention of the 
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effects by the 5-HT4 receptor antagonist, GR-113808, or the Ca
2+
 channel blocker, nifedipine. 
In our study, ISO, with or without 5-HT, induced a relatively greater ICaL increase in cells from 
patients with AF compared to cells from patients in SR, suggesting that the L-type Ca
2+
 channel 
was not the limiting factor for the 5-HT response. The enhanced ICaL response to ISO in cells 
from patients with AF has been reported by others [16-18], but the effects of 5-HT have not 
been studied previously. A reduction of mRNA expression of 5-HT4 receptors in chronic AF has 
been reported [12], but other mechanisms may also contribute to the reduced effects of 5-HT in 
AF. For example, increased activity of protein phosphatases in chronic AF has been shown to be 
associated with reduced basal and ISO-activated ICaL currents [18], and changes in protein 
phosphatases and/or kinases with AF could contribute to the reduced efficacy of 5-HT on ICaL 
current density. The ability of 5-HT to increase cyclic AMP and cyclic AMP-dependent protein 
kinase activity has been shown to be significantly less than that of ISO [6,19,20], although 
similar increases in ICaL were induced by 5-HT and ISO in atrial cells from patients in SR 
[8,19,21]. In addition, changes in the coupling of the stimulatory or inhibitory G-proteins with 
5-HT or ISO receptors may differently affect adenylate cyclase activity leading to the 
phosphorylation/dephosphorylation of the L-type Ca
2+
 channel [22,23]. These and other factors, 
such as the expression of different 5-HT4 receptor subtypes in human atrial cells that couple to 
different Gs/i proteins [24-26], may possibly reflect a physiological adaptation to limit the Ca
2+
 
overload associated with AF [27]. The reduced potency of 5-HT on the ICaL response with AF 
may support altered receptor/channel coupling, in line with the observation of a reduced potency 
of ISO on contractile responses in atrial tissue from patients with AF [28]. 
The proarrhythmic activity induced by β-adrenoceptor agonists (e.g. isoproterenol) has been 
known for a long time [29] and their ability to increase ICaL via activation of the cyclic AMP 
cascade has been highlighted as the main trigger to induce afterdepolarisations in human atrial 
cells [29,30]. Similarly, 5-HT, which activates the same biochemical pathway, has been 
  
17 
 
demonstrated to induce pro-arrhythmic activity in atrial cells from patients in SR, particularly 
in those previously treated with β-adrenoceptor antagonists [9,10]. The reduced efficacy and 
potency of 5-HT to increase ICaL in cells from patients with AF in the present study was 
associated with a loss of pro-arrhythmic activity by 5-HT, which may be directly linked to the 
reduced Ca
2+
 entry [31]. ISO caused a greater increase in ICaL when compared to 5-HT in both 
the SR and AF groups, and this was associated with a greater incidence in the occurrence of 
arrhythmic activity. Similarly, it has been shown previously that the partial 5-HT4 agonist 
prucalopride, in cells from patients in SR, caused reduced Ca
2+
 entry when compared to 5-HT, 
and did not induce arrhythmic activity, while 5-HT, in the same cells, did [32]. In addition, the 
L-type Ca
2+
 channel blocker nifedipine prevented the appearance of 5-HT/ISO-induced cADs, 
suggesting that increased ICaL and cellular Ca
2+
 overload may play a major role in inducing 
cADs in human atrial cells [9,31,32]. Further studies, for example using a combination of 
electrophysiology and Ca
2+
 imaging techniques, are needed to elucidate the mechanisms of the 
observed arrhythmic activity. 
The slowing of the time-dependent ICaL inactivation in AF is consistent with other studies in 
which τ1 and/or τ2, were increased in AF [17,33], possibly reflecting an adaptation to an altered 
activity of the SR Ca
2+
 release channels and/or a reduced Ca
2+
 influx through L-type Ca
2+
 
channels [34,35]. By contrast, 5-HT and ISO decreased the fast time constant (τ1) of ICaL 
inactivation in both the SR and AF groups, and shifted the fast phase to the slow phase, 
suggesting an enhanced Ca
2+
-dependent inactivation probably due the increased release of Ca
2+
 
by ryanodine receptors during stimulation [34].  
One important factor that may affect 5-HT response in human atrium is prior treatment with β-
adrenoceptor antagonists [2,9,10,36]. The present study indicated that chronic β-blockade 
increased the effects of 5-HT on ICaL in cells from patients with and without AF. However, 
while chronic β-blockade potentiated the effects of 5-HT on the APD50 and arrhythmic activity 
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in cells from patients in SR, it did not in cells from patients with AF. In our study we report a 
prolonged basal APD50, together with a reduced basal APD90, in cells from patients with AF, 
consistent with other studies [37,38], but in contrast to other reports of no change in the APD50 
[39] or reduced APD50 with AF [33,40]. Since a maximal concentration of ISO was capable of 
further prolonging the APD50 during perfusion with 5-HT, the prolonged basal APD50 found 
with AF in our study was not preventing a further increase with 5-HT. While it has been 
reported that the levels of mRNA of human atrial 5-HT4-, β1- and β2-adreno-receptors were 
unaffected by chronic β-blockade in cells from patients with and without AF [12], the 
interaction of complex “electrophysiological” [41] and “pharmacological” [42] remodelling 
processes may alter the balance of outward and inward currents which determine the APD50 and 
attenuate the effect of chronic β-blockade on the ICaL responses to 5-HT.  
In conclusion, AF is associated with a reduced efficacy and potency of 5-HT to increase ICaL in 
human atrial cells. The reduced Ca
2+
 current is associated with a reduced duration of the early 
plateau phase of the action potential and an absence of arrhythmic activity with 5-HT. The 
ability of ISO to cause a relatively greater increase in ICaL than 5-HT in cells from patients with 
AF, compared with those in SR, suggests that the reduced efficacy of 5-HT observed with AF 
was not due to reduction in L-type Ca
2+
 channels but may involve other factors, such as reduced 
density of the 5-HT4 receptors or alterations of coupling mechanisms. Thus, the potentially 
arrhythmogenic influence of 5-HT may be suppressed in human atrium that has been 
remodelled by AF. 
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Legends for Figures and Tables 
 
 
Table 1.  
Patients’ pre-operative clinical characteristics 
Values are numbers of patients (n and % of total, respectively) with selected clinical 
characteristics, who were in SR or with AF on the day of surgery. Age is expressed as 
mean±SEM. CABG=coronary artery bypass graft surgery, AVR=aortic valve replacement, 
MVR=mitral valve replacement, RAA=replacement ascending aorta, ACE=angiotensin 
converting enzyme, MI=myocardial infarction, LVD=left ventricular dysfunction. 
 
 
Table 2.  
Kinetic properties of the time-dependent inactivation of ICaL 
Time-dependent inactivation of ICaL was fitted by a bioexponential function and was defined by 
the following equation: ICaL(t)=A1.exp(-t/τ1)+A2.exp(-t/τ2)+C, where A1, A2 and τ1, τ2 are the 
amplitudes and decay time constants of the respective exponential components, and C is the 
steady state amplitude. Data are expressed as mean±SEM in cells from patients in SR or with 
AF, in the absence or in the presence of 5-HT (10 µM), or co-applied with ISO (1 µM). The 
asterisks indicates p<0.05 vs SR control (*) or vs AF control (**), using paired or unpaired 
Student’s t-tests, as appropriate. 
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Figure 1. 
Effects of 5-HT on ICaL current-voltage relationship 
An example of original ICaL traces obtained from a cell from a patient in SR (left panel) or with 
AF (right panel), during depolarising voltage clamp pulses (250 ms) from -40 mV to +40 mV, 
in 10 mV incremental steps, from a holding potential of -40 mV, under control conditions (open 
symbols) and in the presence of 5-HT at 10 µM (closed symbols) is shown. As an inset, current-
voltage relationships of ICaL expressed in terms of current density, pA/pF, in cells from patients 
in SR (n=28 cells, 16 patients) or with AF (n=21 cells, 11 patients) are shown. Values are 
expressed as means± SEM. 
 
 
Figure 2. 
Concentration-dependent effects of 5-HT on peak ICaL  
Comparison of the concentration-response relationship for 5-HT-induced increase in peak ICaL 
density (pA/pF) in cells from patients in SR (0.001-10 µM; solid squares; n=23-52 cells, 11-31 
patients) or with AF (0.001-10 µM; solid circles; n=26-31 cells, 12-14 patients) is shown in 
Figure 2A. Values are means ±SEM. The increase in ICaL is expressed as absolute value of 
change compared to before the addition of 5-HT. Comparison of the calculated best-fit values 
for the Emax (Figure 2B) and EC50 (Figure 2C) are shown between cells from patients in SR or 
with AF. The asterisk indicates p<0.05 (unpaired Student’s t-test). 
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Figure 3. 
Influence of chronic β-blockade on concentration-dependent effects of 5-HT on peak ICaL 
Figure 3A shows a comparison of concentration-response curves for 5-HT-induced increase of 
peak ICaL density (pA/pF) between cells from patients in SR treated (BByes; n=15-37 cells, 7-22 
patients) and not treated (BBno; n=8-17 cells, 4-9 patients) with a β-adrenoceptor antagonist 
(open symbols), and those from patients with AF treated (BByes; n=11-18 cells, 5-7 patients) 
and not treated (BBno; n=13-16 cells, 5-6 patients) with a β-adrenoceptor antagonist (closed 
symbols). Comparison of the calculated best-fit values for the Emax (Figure 3B) and EC50 (Figure 
3C) are shown between groups of patients. Asterisk denotes p<0.05 (paired or unpaired 
Student’s t-test), with NS equal to p>0.05 (not statistically significant).  
 
 
Figure 4. 
Effects of 5-HT, with and without ISO, on peak ICaL 
An example of the time course of change in peak ICaL density (pA/pF) plotted at 5 s resolution, 
in response to 10 µM 5-HT, followed by the co-application of ISO at 1 µM, and the subsequent 
washout of drugs in a cell from a patient in SR or with AF are shown in Figure 4A and 4B, 
respectively. Inset traces (a-d) show original currents recorded at the time points labelled. 
Figure 4C shows mean (±SEM) ICaL data, in the absence (open bars), in the presence of 10 µM 
5-HT (closed bars) or co-applied with 1 µM ISO (crossed bars), measured in cells from patients 
in SR (n=27 cells, 12 patients; open circles) or with AF (n=10 cells, 6 patients; closed circles). 
Subsequent re-application of ISO alone following the washout of 5-HT+ISO is also shown for 
both SR (n=7 cells from 5 patients) and AF (4 cells from 2 patients) groups. Asterisk denotes 
p<0.05 (paired or unpaired Student’s t-test). 
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Figure 5. 
Effects of 5-HT on action potentials characteristics 
Representative examples of original action potential recordings before (open circles), in the 
presence of 10 µM 5-HT (closed circles), and then following 3 min wash (open squares), from 
cells from patients in SR (left panel) or with AF (right panel), both treated with a β-
adrenoceptors antagonist, are shown in Figure 5A. Cells were paced at 75 bpm. Dotted lines in 
bold show the level of 50% of the action potential amplitude. The cellular ERP is indicated by 
solid bars and was defined as described in the Methods section. Figure 5B shows the increase in 
APD50 (ms) by 5-HT (10 µM), measured in cells from patients in SR (n= 58 cells, 24 patients) 
or with AF (n=37 cells, 14 patients). Asterisk denotes p<0.05 (unpaired Student’s t-test). 
 
 
Figure 6. 
Effects of 5-HT, with and without ISO, on arrhythmic activity 
Figure 6A shows an example of original recordings of action potentials obtained from a cell 
from a patient in SR (left panel) or with AF (right panel), before (open circle), in the presence of 
10 µM 5-HT (solid circle), 10 µM 5-HT+1 µM ISO (striped circle) and then following 3 min 
washout (open square) or attenuation of ISO-induced cADs by 10 µM nifedipine (solid square). 
Figure 6B shows the incidence of cADs (%) in cells from patients with and without AF, which 
occurred during the application of 5-HT at 10 µM (closed bars) or co-applied with ISO at 1µM 
(crossed bars). Asterisks denotes p<0.05 (Fisher’s exact test). 
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 Table 1. Patient’s preoperative clinical characteristics 
 SR AF 
 n (%) n (%) 
Patients 66  15  
Male/female 46/20 70/30 9/6 60/40 
Age 65±1   69±2  
Surgery     
CABG 55 (83) 1 (7) 
AVR 2 (3) 3 (20) 
MVR 1 (2) 7 (47) 
AVR+MVR 0 (0) 1 (7) 
CABG+AVR 7 (11) 1 (7) 
CABG+MVR 1 (2) 1 (7) 
MVR+RAA 0 (0) 1 (7) 
Drugs     
Ca
2+
 channel blocker 31 (47) 3 (20) 
Beta blocker 47 (71) 8 (53) 
ACE inhibitor 38 (58) 7 (47) 
Nitrate 42 (64) 3 (20) 
Diuretic 22 (33) 9 (60) 
Lipid lowering 56 (85) 7 (47) 
Digoxin 0 (0) 9 (60) 
Warfarin 1 (2) 12 (80) 
Symptoms     
Angina 61 (92) 8 (53) 
Palpitations 12 (18) 6 (40) 
Hypertension 40 (61) 8 (53) 
Hyperlipidaemia 52 (79) 5 (33) 
Previous history     
MI 29 (44) 1 (7) 
Diabetes 12 (18) 2 (13) 
LV function     
 -normal 48 (73) 9 (60) 
-mild-moderate LVD 17 (26) 5 (33) 
-severe LVD 1 (2) 1 (7) 
  
32 
 
 
 
Table 2. Kinetic properties of the time-dependent inactivation of ICaL 
 
 
 τ1 (ms) τ2 (ms) A1 (%) A2 (%) 
SR Control 6.2±0.5 41±4 72±2 28±2 
SR 5-HT 5.7±0.5 40±2 66±2* 34±2* 
SR 5-HT+ISO 5.5±0.4* 41±2 60±3* 40±3* 
SR Wash 7.8±0.9 52±3 71±2 29±2 
AF Control 14.7±1.7* 69±11* 80±4 20±4 
AF 5-HT 12.4±2.6 71±14 74±3** 26±3** 
AF 5-HT+ISO 9.9±1.8** 65±12 62±7** 38±7** 
AF Wash 16.9±3.3 85±12 77±3 23±3 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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